CA2021637C - Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them - Google Patents
Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing themInfo
- Publication number
- CA2021637C CA2021637C CA 2021637 CA2021637A CA2021637C CA 2021637 C CA2021637 C CA 2021637C CA 2021637 CA2021637 CA 2021637 CA 2021637 A CA2021637 A CA 2021637A CA 2021637 C CA2021637 C CA 2021637C
- Authority
- CA
- Canada
- Prior art keywords
- complexes
- krameria
- phospholipids
- natural
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Complexes of lipophilic extracts from plants of Krameria or Eupomatia genus and of some neolignanes isolated from the same extracts with natural or synthetic phospholipids; said complexes proved to have antiradical, antibacterial and antimycotic activities, so as to be useful as novel active principles for preparing medicaments and cosmetics. Due to the antioxidant, antibacterial and antimycotic activities thereof they can be used as natural preservatives in pharmaceutical and cosmetic formulations.
Description
co~zz~x~s o~ NFOLZCN~raE DERZVATZ~s r~zTa raosPaoLZrzos, TaE asp Ts~REOF ANn pa~RM~.cEaTIC~. ANn cos~~IC ~o~
TIONS CONTAINING THE~3.
The present invention relates to complexes of extracts from Krameria triandra Ruiz et Pav. and other plants of the Eupomatia genus, as well as some phenol constituents thereof of neo-lignane "or nor-neolignane nature, with phospholipids; to the processes for the preparation of said extracts and complexes, and to pharmaceutical compositions containing them:
The extracts from roots of Krameria triandra had been used widely in the past as medicaments, thanks to both the astringent property thereof, due to the presence of Ratania-tannin, and the antiinflammatory, antidiarrhoeal and antibacterial properties connected with other components; some of those characteristics are reported on Martindale, ~~The extrapharmacopeia~~, 28th Ed. (1982) and on other documents (Canizzaro, Boll. Soc.
Ital. Biol. Sperim., 1, 22, 1964; and V. Hoppe, Drogenkunde Bdl Walter De Gruyter ed., 1975). Two components of neolignane nature have been described as sunscreens for possible cosmetic use (Stahl, Planta Med., 42, 144, 1981). The first remarks on the medicinal properties of said plant go back to the Peruvian people empiricism, which used the roots for the oral cavity hygiene (~~raiz para los dientes~~), which use spread rapidly also in other countries in more recent times.
British patent 2.184.353A claims the antibacterial and antimycotic properties of extracts from Krameria triandra and of some components, called Ratania-phenols, for which the use by the topical route is envisaged for the treatment of acne, dermatomycosis and decubitus ul-cers attributable to infections caused by aerobic and anaerobic strains. A renewed interest in Krameria trian-dra derivatives came out from Italian preliminary sear ches, the results of which, related to the antibacterial and antimycotic activities, were reported in the 1st Int. Symposium on Organic Chemistry of Medicinal Natural Products, Shanghai, and also in a degree thesis at the University of Milan.
From the above cited literature data, the antibac-terial and antimycotic activities turn out to be essen-tially related to Ratania-phenols of neolignane nature;
said compounds showing in vitro a remarkable antimicro-bial activity which, as we could ascertain, almost com-pletely disappears after administration of the compounds by the systemic route, since the phenol groups easily undergo oxidation, or other enzyme degradations can occur. Topical treatments with total or purified extracts also show to a considerable degree the same drawbacks of the systemic route, thus decreasing the effectiveness of the active principles.
Now, it has surprisingly been found that, by reac ting these substances with phospholipids in aprotic sol vents, to generate the lipophilic complexes disclosed hereinafter, the same antimicrobial activities of the free active principles can be obtained in vitro, with a simultaneous remarkable improvement in the in vivo anti-microbial, antiinflammatory arid antiradical activities.
zn order to prepare the above mentioned complexes, either the main components of the Ratania-phenol class, such as Eupomatenoid 6 or the compound 2(2,4-dihydroxy-phenyl)-5-propeny:Lbenzofuran, which is among the main responsibles for the biological activity, or purified extracts standardized in these active principles have been used, the latter being prepared chiefly by extracting the roots with chlorinated solvents such as methylene chloride, chloroform, dichloroethane, etc. and partitioning the concentrate. between an aliphatic alcohol and an aliphatic or aromatic hydrocarbon.
ZO Generally the roots are extracted with methylene chloride, the percolate is concentrated to small volume and the residue is dissolved in 90°~ aqueous methanol and counter-extracted with n-hexane; the methanol phase, after appropriate dilution with water, is counter-l5 extracted with a chlorinated solvent which extracts the active principles; the chlorinated organic phase is concentrated to small volume and the residue is insolubilized with n-hexane.
According to a preferred object of the present in 20 vention, in order to maintain the stability of the ac tive principles during the extraction processes, the fi nely ground roots are extracted with carbon dioxide un der hypercritical conditions, working at a temperature of 40°C and under a pressure of 120 bars; after the ex 25 traction under said conditions, the vegetable material is further extracted with carbon dioxide added with ace-tone, at a temperature of 45°C and under a pressure of 200 bars; the residue from this second extraction, after evaporating off the gas, is dissolved in methylene chlo-~0 ride, dehydrated, decolorized on charcoal and insolubilized in hexane.
~Q~~~3'~
TIONS CONTAINING THE~3.
The present invention relates to complexes of extracts from Krameria triandra Ruiz et Pav. and other plants of the Eupomatia genus, as well as some phenol constituents thereof of neo-lignane "or nor-neolignane nature, with phospholipids; to the processes for the preparation of said extracts and complexes, and to pharmaceutical compositions containing them:
The extracts from roots of Krameria triandra had been used widely in the past as medicaments, thanks to both the astringent property thereof, due to the presence of Ratania-tannin, and the antiinflammatory, antidiarrhoeal and antibacterial properties connected with other components; some of those characteristics are reported on Martindale, ~~The extrapharmacopeia~~, 28th Ed. (1982) and on other documents (Canizzaro, Boll. Soc.
Ital. Biol. Sperim., 1, 22, 1964; and V. Hoppe, Drogenkunde Bdl Walter De Gruyter ed., 1975). Two components of neolignane nature have been described as sunscreens for possible cosmetic use (Stahl, Planta Med., 42, 144, 1981). The first remarks on the medicinal properties of said plant go back to the Peruvian people empiricism, which used the roots for the oral cavity hygiene (~~raiz para los dientes~~), which use spread rapidly also in other countries in more recent times.
British patent 2.184.353A claims the antibacterial and antimycotic properties of extracts from Krameria triandra and of some components, called Ratania-phenols, for which the use by the topical route is envisaged for the treatment of acne, dermatomycosis and decubitus ul-cers attributable to infections caused by aerobic and anaerobic strains. A renewed interest in Krameria trian-dra derivatives came out from Italian preliminary sear ches, the results of which, related to the antibacterial and antimycotic activities, were reported in the 1st Int. Symposium on Organic Chemistry of Medicinal Natural Products, Shanghai, and also in a degree thesis at the University of Milan.
From the above cited literature data, the antibac-terial and antimycotic activities turn out to be essen-tially related to Ratania-phenols of neolignane nature;
said compounds showing in vitro a remarkable antimicro-bial activity which, as we could ascertain, almost com-pletely disappears after administration of the compounds by the systemic route, since the phenol groups easily undergo oxidation, or other enzyme degradations can occur. Topical treatments with total or purified extracts also show to a considerable degree the same drawbacks of the systemic route, thus decreasing the effectiveness of the active principles.
Now, it has surprisingly been found that, by reac ting these substances with phospholipids in aprotic sol vents, to generate the lipophilic complexes disclosed hereinafter, the same antimicrobial activities of the free active principles can be obtained in vitro, with a simultaneous remarkable improvement in the in vivo anti-microbial, antiinflammatory arid antiradical activities.
zn order to prepare the above mentioned complexes, either the main components of the Ratania-phenol class, such as Eupomatenoid 6 or the compound 2(2,4-dihydroxy-phenyl)-5-propeny:Lbenzofuran, which is among the main responsibles for the biological activity, or purified extracts standardized in these active principles have been used, the latter being prepared chiefly by extracting the roots with chlorinated solvents such as methylene chloride, chloroform, dichloroethane, etc. and partitioning the concentrate. between an aliphatic alcohol and an aliphatic or aromatic hydrocarbon.
ZO Generally the roots are extracted with methylene chloride, the percolate is concentrated to small volume and the residue is dissolved in 90°~ aqueous methanol and counter-extracted with n-hexane; the methanol phase, after appropriate dilution with water, is counter-l5 extracted with a chlorinated solvent which extracts the active principles; the chlorinated organic phase is concentrated to small volume and the residue is insolubilized with n-hexane.
According to a preferred object of the present in 20 vention, in order to maintain the stability of the ac tive principles during the extraction processes, the fi nely ground roots are extracted with carbon dioxide un der hypercritical conditions, working at a temperature of 40°C and under a pressure of 120 bars; after the ex 25 traction under said conditions, the vegetable material is further extracted with carbon dioxide added with ace-tone, at a temperature of 45°C and under a pressure of 200 bars; the residue from this second extraction, after evaporating off the gas, is dissolved in methylene chlo-~0 ride, dehydrated, decolorized on charcoal and insolubilized in hexane.
~Q~~~3'~
From the above prepared extracts, the single pure components can be isolated, using chromatography techni-ques on silica gel, working on the her se products or, preferably, on the acetyl derivatives thereof, which are subsequently deprotected under controlled conditions.
The above cited extracts contain about 50% Eupo-matenoid 6 and 25% 2(2,4-dihydroxyphenyl)-5-propenyl-benzofuran, as determined by g.as chromatography or by I~PLC. These substances, at the pure state, and the ex-tracts containing them have been tested in vitro for the antiradical, antibacterial and antimycotic activities thereof, both as the free compounds and as the complexes thereof, and in vivo for the antiinflammatory and anti-microbial activities.
The obtained data are reported in Tables I, II and III.
The in vitro antimicrobial activity (M.I.C, expres-sed in mcg/ml) was evaluated in agar culture medium Isosensitest agar pxoid on Gram-positive and Gram-nega-tive microorganisms from both collection and hospital isolation; Difco blood agar was used for streptococci, whereas Sabouraud maltose agar Difco was used for yea-sts, moulds and dermatophytes, by incubating the various inocula according to standard procedures. The results are reported in the following Table I.
_ 5 _ fable I
Antimicrobial activity of Kra~ria active principles and of the related canplexas.
Microorgar..a.sm M.I.C.mcg/m1 I II III IV V VI
Staphylococ.aureus 0.0120.78 1.563.12 1.560.78 ~nith Staphylococ.aureus 0.0240.78 1.561.56 1.563.12 Staphylococ.aureus 50 0.78 1.563.12 1.563.12 F2*G
Staphylococ.aureus 0.0120.78 1.563.12 1.563.12 Staphylococ.aureus 3.12 0.78 0.783.12 1.561.56 OSCB*
Staphylococ.aureus 0.78 0.78 1.561.56 1.561.56 FBF*
Streptococ.pyogenes 0.0120.39 0.783.12 3.121.56 Streptococ.pyogenes 0.0120.39 0.783.12 0.650.65 Streptococ.faeca7.is 0.19 1.56 3.123.12 6.256.25 Streptococ.faecalis 0.39 3.12 6.256.25 6.256.25 Streptococ.salivarius0.78 6.25 0.7812.5 1.5612.5 Streptococcus. mutans0.0120.78 0.781.56 1.563.12 Stxeptcccc.pyogenes 0.19 0.78 0.780.78 1.566.25 Streptoccc.mitis 77/2310.78 1.56 1.561.56 0.783.12 Sarcinia lutea 9341 0.0120.39 0.780.39 1.563.12 Fscherichia coli 120 0.39 >200 50 >200 100 100 Salmonella typhi 6/120.19 >100 25 >100 50 >100 Salmonella errteritidis0.78 200 50 >200 100 >100 2 Neisseria meningitides0.0121.56 0.781.56 1.563.12 Klebsiella pneuie >200 >200 12.5>200 12.5>100 Table I (continued) Microorganism M.I.C. mcg/ml I II III TV V VI
Candida albicans G1 3.12 6.25 25 6.25 6.25 >200 Aspergillus niger 6.25 6,25 12.5 6.25 12.5 100 Trichophyton mentag. 0.39 1.56 1.56 1.56 1.56 25 Trichophyton tonsurans 0.19 0.78 1.5~ 1.56 0.78 12.5 Microsporum cams L/55 0.78 1.56 0.78 3.12 1.56 12.5 Substances I = ampicillin for bacteria and miconazole for fungi.
II = Eupomatenoid 6.
III = 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
IV = Complex of Eupomatenoid with phosphatidylcholine.
V = complex of 2(2,4-dihydroxyphenyl)-5-propenylbenzo ,,,v i ~L
furan c~hi~ phosphatidylcholine.
VI = Standardized Krameria extract.
The antiinflammatory activity by the topical route was evaluated in the mouse by the Croton oil test, ac cording to the procedures reported in Agents and Ac tions, 17, 347-49, 1985. The results are summarized in the following Table II.
The above cited extracts contain about 50% Eupo-matenoid 6 and 25% 2(2,4-dihydroxyphenyl)-5-propenyl-benzofuran, as determined by g.as chromatography or by I~PLC. These substances, at the pure state, and the ex-tracts containing them have been tested in vitro for the antiradical, antibacterial and antimycotic activities thereof, both as the free compounds and as the complexes thereof, and in vivo for the antiinflammatory and anti-microbial activities.
The obtained data are reported in Tables I, II and III.
The in vitro antimicrobial activity (M.I.C, expres-sed in mcg/ml) was evaluated in agar culture medium Isosensitest agar pxoid on Gram-positive and Gram-nega-tive microorganisms from both collection and hospital isolation; Difco blood agar was used for streptococci, whereas Sabouraud maltose agar Difco was used for yea-sts, moulds and dermatophytes, by incubating the various inocula according to standard procedures. The results are reported in the following Table I.
_ 5 _ fable I
Antimicrobial activity of Kra~ria active principles and of the related canplexas.
Microorgar..a.sm M.I.C.mcg/m1 I II III IV V VI
Staphylococ.aureus 0.0120.78 1.563.12 1.560.78 ~nith Staphylococ.aureus 0.0240.78 1.561.56 1.563.12 Staphylococ.aureus 50 0.78 1.563.12 1.563.12 F2*G
Staphylococ.aureus 0.0120.78 1.563.12 1.563.12 Staphylococ.aureus 3.12 0.78 0.783.12 1.561.56 OSCB*
Staphylococ.aureus 0.78 0.78 1.561.56 1.561.56 FBF*
Streptococ.pyogenes 0.0120.39 0.783.12 3.121.56 Streptococ.pyogenes 0.0120.39 0.783.12 0.650.65 Streptococ.faeca7.is 0.19 1.56 3.123.12 6.256.25 Streptococ.faecalis 0.39 3.12 6.256.25 6.256.25 Streptococ.salivarius0.78 6.25 0.7812.5 1.5612.5 Streptococcus. mutans0.0120.78 0.781.56 1.563.12 Stxeptcccc.pyogenes 0.19 0.78 0.780.78 1.566.25 Streptoccc.mitis 77/2310.78 1.56 1.561.56 0.783.12 Sarcinia lutea 9341 0.0120.39 0.780.39 1.563.12 Fscherichia coli 120 0.39 >200 50 >200 100 100 Salmonella typhi 6/120.19 >100 25 >100 50 >100 Salmonella errteritidis0.78 200 50 >200 100 >100 2 Neisseria meningitides0.0121.56 0.781.56 1.563.12 Klebsiella pneuie >200 >200 12.5>200 12.5>100 Table I (continued) Microorganism M.I.C. mcg/ml I II III TV V VI
Candida albicans G1 3.12 6.25 25 6.25 6.25 >200 Aspergillus niger 6.25 6,25 12.5 6.25 12.5 100 Trichophyton mentag. 0.39 1.56 1.56 1.56 1.56 25 Trichophyton tonsurans 0.19 0.78 1.5~ 1.56 0.78 12.5 Microsporum cams L/55 0.78 1.56 0.78 3.12 1.56 12.5 Substances I = ampicillin for bacteria and miconazole for fungi.
II = Eupomatenoid 6.
III = 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
IV = Complex of Eupomatenoid with phosphatidylcholine.
V = complex of 2(2,4-dihydroxyphenyl)-5-propenylbenzo ,,,v i ~L
furan c~hi~ phosphatidylcholine.
VI = Standardized Krameria extract.
The antiinflammatory activity by the topical route was evaluated in the mouse by the Croton oil test, ac cording to the procedures reported in Agents and Ac tions, 17, 347-49, 1985. The results are summarized in the following Table II.
7 _ Table II
Antiinflammatory activity the Krameriaextract, of of the active components thereofand of the related com-plexes in the Croton oil in the mouse,at the maxi-test s mum edema (6 hours).
Substances Dose/mcg/ear Edema mg % reduction Controls --- .7.410.2 ---Eupomatenoid 6 56 1.50.2 78.5 **
28 4.50.1 40.2 Ratania-phenol* 56 1.90.2 73.7 **
28 4.70.2 34.8 Krameria extract 70 1.80.3 75.0 **
Phospholipid 157 6.50.3 10.2 78 6.20.2 14.0 Eupomatenoid/
complex 1M:11'~1 96 1.90.2 73.7 **
Krameria extr./
Complex lp:2p(w/w) 105 1.60.3 78.2 **
________________________________________________________ * 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
Distearoylphosphatidylcholine.
P<0.01 Student t.
The antiradical activity was evaluated using DPPH
as the competitor, accordingto proceduresdescribed in literature. Following Table obtained III reports the re-sults.
~~~1~3'~
_8-Table III
Antiradical activity of a Krameria standardized extract and of two components thereof.
Substances Conc.mcg/ml % destroyed DPNH
Eupomatenoid 6 6.6 -75.7 2.8 . -40.8 Ratania-phenol* 6.6 -80.5 2.8 -46.4 Krameria extract 10 -72.4 5 -41.6 Quercetin 6.2 -68.2 * 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
In order to prepare the complexes with phospholi-pids, pure soy phosphatidylcholine or standardized mixtures of vegetable phospholipids with titres from 90°6 to 100°,~ or pure synthetic phospholipids having saturated or unsaturated acyl chains and choline or ethanolamine as the basic portion, were selected as the complexing agent s .
The formation of said complexes is ascertained by means of 1H-NMR, 13C-NMR, 31P-NMR spectroscopies and so lubility tests. As regards solubility, substances which are insoluble in aprotic solvents such as aromatic hydrocarbons, become easily soluble after complexation;
in the lIi-NMR spectrum the signals of complexed substances undergo a strong broadening, so as they can no more be evidenced in the spectra; in the 13C-NMR
spectrum the signals of the complexed substance, as well ".
_ g _ as those of the choline and glyceryl portions of the phospholipid, can no more be recorded; the phosphorus nucleus itself undergoes a band broadening, which indicates it is involved in the complex formation; in both the 1H and the 13C spectra, substantially only the lipid chain signals appear, even showing some immobilization. The above data prove the interaction between the phospholipid polar head and the active sites of the complex, whereas the lipid chains are not i0 involved, since they are free to rotate and can wind the complexed molecule giving it a marked lipophilia.
This winding clearly results in a particular steric ' configuration when the complex is dispersed in an aqueous medium, giving stability to the molecules them-selves.
The complexes of the present invention are insolu-ble in water and cannot form in this medium, therefore associations of the same products with phospholipids or liposomal preparations thereof do not give the same bio-logical results; the complexes of the invention, due to dipolarity reasons, in aqueous medium give rise to micellar microdispersions remarkably similar to the liposome structures. The novel structures according to the invention show, in comparison with the same structures in the free form, a different in vivo bioavailability which involves an increase in the specific activity as well as a longer lasting action by the topical route (skin and accessible mucosae).
For this class of substances, phospholipids are a selective carrier allowing the molecules to have both an improved crossing of the horny layer of the skin and a 202~.~~'~
better interaction with cell and bacterial walls. The molecules in the free form are restored and retained in the action site for a longer time. The presence of a surfactant, i.e. the phospholipid, in the molecule, al-lows to obtain a higher adhesion of the product itself to the surfaces it comes into contact with. This aspect is of paramount importance in cosmetic and pharmaceuti-cal formulations intended for the treatment of the oral cavity, in which contact times are of course very short;
the opportunity to increase the adhesion of the product to mucosae or to the tooth surface and to make the va-rious molecules interact with cell structures is of basic practical importance and it is an object of the present invention.
The dosages of the complexes of the invention can range widely, depending on the intended therapeutical purposes, and they can vary from 0.001 to 1°,6. The com-plexes of the present invention can be incorporated in the traditional pharmaceutical forms, such as ointments, fluid and thick 0/W or W/0 emulsions, solutions, chewa-ble tablets, dusting powders, or in form of plasters or medicated gauzes. Said preparations can be used in hu-mans or in animals for the treatment of superficial in-fected inflammatory processes, in torpid sores and in all the phlogistic conditions of the oral cavity; more particularly, as far as the oral cavity is concerned, they are an effective protection against the formation of dental plaque, when administered in form of medicated toothpaste, collutory or gel. In the cosmetic field, said complexes can be used for the treatment of acne and as deodorant, antidandruff and personal hygiene pro-ducts .
The following non limiting examples further illu-strate the invention.
Preparation of a standardized Krameria triandra extract.
kg of finely ground roots of Krameria triandra are extracted 4 times under mild reflux and nitrogen atmo-sphere with 4 volumes of methylene chloride; the combi-ned extracts are concentrated to small volume under nor-10 mal pressure. The concentrate is taken up into 5 1 of 90°,6 aqueous methanol and the solution is extracted 3 ti-mes with 1.5 1 of n-hexane; the hexane phase is discar-ded since it contains no active principles whereas the methanol phase is concentrated to 1.2 1; this concen-trace is extracted 3 times with 1.5 1 of methylene chlo-ride. The hydroalcoholic phase is discarded, whilst the chloromethylene extracts are pooled and treated with 25 g of decolorant charcoal in the presence of anhydrous sodium sulfate as the dehydrating agent; the decolorized chloromethylene solution is concentrated to small volume and the concentrate is poured into 1.5 1 of hexane, un-der. strong stirring. The precipitate is filtered and dried under vacuum overnight at 40°C, to obtain 300 g of a product containing about 50°,~ Eupomatenoids and 27%
2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
Preparation of Eupomatenoid 6 and 2-(2,4-dihydroxyphe-nyl)-5-propenylbenzofuran.
100 g of an extract prepared according to the pro cedures reported in Example 1 are chromatographed on a column containing 1.5 kg of silica gel, which has pre viously been equilibrated with a toluene/ethyl acetate 9:1 mixture, eluting the products with the same solvent mixture; the fractions showing a similar composition by thin layer chromatography are pooled and concentrated to dryness. The more abundant fraction, containing Eupoma-tenoid 6 (54 g) is crystallized from an hexane-isopropyl ether mixture, thus recovering the pure compound; analo-gously, the fraction containing the benzofuran deriva-tive is crystallized so as to isolate also this com-pound, the physico-chemical and speetroscopical charac-teristies of which are the same as those reported in li-terature.
Preparation of a purified Krameria extract by means of carbon dioxide under supercritical conditions.
1.5 kg of finely ground roots of Krameria are ex-tracted continuously in a suited reactor, fitted with heating and cooling mantle, with carbon dioxide under supercritical conditions, in two steps. A first step is carried out at a temperature of 35°C and under a pres-sure of 110 bars; in the evaporator temperature and pressure are 25°C and 50 bars, respectively. Two hours after, the extracted material is unloaded from the condenser and carbon dioxide containing 1.5% acetone is circulated in the extractor. The first extract, containing only lipophilic substances with no activity, is discarded, whereas the second extract is collected, which is obtained by increasing temperature to 45°C and pressure to 200 bars. The collected extract in the condenser is dissolved in isopropyl ether, the solution is dried over sodium sulfate and subsequently concentrated to small volume. The concentrate is poured into n-hexane . an abundant precipitate forms which, upon drying, weighs 46 g and has the same composition as that of the product obtained in Example 1, but it has a markedly lighter colour.
Preparation of the complex of the standardised extract of Krameria with soy phosphatidy~lcholine.
1.5 g of a purified Krameria triandra extract are dissolved together with 3 g of soy phosphatidylcholine in 30 ml of methylene chloride and heated to mild reflux for 2 hours; the chloromethylene solution is concentra ted to dryness under vacuum at 30°C until the solvent is completely evaporated off. The 1H-NMR spectrum of the obtained product shows protonic signals at 0.8 ppm of aliphatic methyls of the lipid chains and CH2 signals between 1.5 and 2.8 ppm, a very broad N-CH3 signal at about 3 ppm, signals of hydrogens on the double bond of aliphatic chains at 5.5 ppm and very broad, unresolved signals of aromatic protons of the Ratania-phenols at 6-8 ppm. In the 13C-NMR spectrum, the signals characteri-stics of Ratania-phenols between 102 and 135 ppm are absent or unresolved, and the signals of the carbons of phospholipid glycerin portion are also absent or extre-melt' broadened, as well as those of the choline portion.
Preparation of the complex of Eupomatenoid 6 with soy phosphatidylcholine.
2.8 g (O.OI mole) of Eupomatenoid 6 are dissolved together with 7.8 g (0.001 mole) of pure soy phospha tidylcholine in 30 ml of dioxane free from peroxides and the solution is freeze-dried; 10.5 g of a white product are obtained, having m.p. 98-101°C and spectroscopic characteristics in conformity with those of a complex.
1H-NMR (C6D6 solution): strong broadening of aromatic protons at 6-8 ppm; broadening of the N-CH3 signal at 3.3 ppm. The characteristic signals of lipid chains appear at 0.5-2 ppm. 13C-NMR (C6D6 solution) . absence of the signals of carbons of Eupomatenoid at 105-140 ppm and also of the lipid signals at 60-80 ppm.
Preparation of the complex of 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran with distearoylphosphatidylcholine.
2.78 g of 2-(2,4-dihydroxyphenyl)-S-propenylbenzo-furan are dissolved in 50 ml of dioxane together with 7.95 g of distearoylphosphatidylcholine and heated under strong stirring for 3 hours at SO°C, under argon atmo sphere. When dissolution is completed the whole is freeze-dried, to obtain a white-beige product having spectroscopic characteristics corresponding to those of a complex.
Preparation of a standardized extract of Eupomatia lau-rina.
10 kilograms of finely ground roots of Eupomatia laurina are extracted under weak reflux in a nitrogen atmosphere with 4 volumes of methylene chloride for four times and the pooled extracts are concentrated to a small volume at ordinary pressure. The concentrate is then dissolved in 2 1 of 90 per cent aqueous methanol and the resulting solution is extracted three times with 1.5 1 of petroleum ether.
The petroleum ether phase not containing the active principles is discarded and the methanolic phase is concentrated to 0.9 1. The latter concentrate is diluted with 300 ml of water and extracted three times with 0.8 1 of methylene chloride. The hydroalcoholic phase is discarded and the pooled methylene chloride extracts are treated with 25 g of decolorizing charcoal in the presence of anhydrous sodium sulphate as dehydrating agent. The decolorized methylene chloride solution is concentrated to a small volume and the concentrate is poured under vigorous shaking into 1 1 of hexane. After filtration of the precipitate and overnight drying under vacuum at 40°C, 190 g are obtained of a product which contains as a major component Eupomatenoide 6.
Preparation of the complex between the standardized extract of Eupomatia laurina and soy-bean phosphatidyl-choline.
g of purified extract of Eupomatia laurina are 20 dissolved together with 40 g of soy-bean phosphatidyl choline in 300 ml of methylene chloride and heated under weak reflux for 2 h. The methylene chloride solution is concentrated to dryness under vacuum at 30°C until the solvent has been completely removed. 'rhe 1H-NMR spectrum of the final product shows protonic singnals at 0.8 ppm originating from the aliphatic methyl group of the lipidic chains, CH2 signals between 1.5 and 2.8 ppm, a very broadened N-CH3 signal at around 3.4 ppm, signals from hydrogens on double bonds of aliphatic chains at S.S ppm and very broadened unresolved signals of the aromatic protons of phenols Eupomatenoide 6 like substances between 6.2 and 8 ppm. In the carbon spectra it is remarkable the absence or the lack of resolution of the typical signals of the Eupomatenoide like substances between 102 and 135 ppm and absence or the the extreme broadening of the signals the carbons of belonging to the glycerine and choline portions of the phospholipid. This complex is freely soluble in the chorinated solvents and in the vegetal, oils.
Preparation of a toothpaste containing complex of the the standardized Krameria extract.
100 g contain Complex of Rrameria standardized extract0.1 g Sodium carboxymethyl cellulose m.v. 1.0 "
Sorbitol 70% 20.0 ' Glycerin 18.0 "
Colloidal silica 15.0 "
Titanium dioxide 2.5 "
Maize starch 2.0 "
Sodium laurylsulfate 2.0 "
Sodium laurylsarcosinate 30% s. a. 1.0 "
Flavouring composition 1.0 ' Purified water q.s.to 100.0 "
Preparation of chewable tablets containingthe complex of Krameria standardized extract.
Each 1 g tablet contains Complex of Krameria standardized extract5.0 mg Methyl cellulose m.v. 2.0 "
Colloidal silica g.0 ~~
Magnesium stearate 10.0 "
-- 17 _ Mannitol 250.0 "
Glycamil (monoammonium glycyrrhizinate)5.0 "
Flavours 20.0 "
Saccharose (compressible) 700.0 mg Preparation of a medicated cream containing the complex Eupomatenoid/phosphatidylcholine.
100 g of an O/W emulsion contain Complex Eupomatenoid/phosphatidylcholine0.1 g PEG-8 C12-18 alkyl ester 10.0 "
Glyceryl stearate and PEG-8 stearate 2.5 "
Isopropyl myristate Preservative 0.1 "
Glycerin 5.0 ' Perfumed composition 0.5 "
Purified water q.s.to 100.0 g Preparation of an aqueous gel containingthe complex of the Krameria standardized extract 100 g of gel contain :
Complex of standardized Krameria extract0.1 g PEG-6 caprylic/capric glycerides 10.0 "
Ethoxylated oleyl alcohol 5.0 "
Carboxyvinyl polymer 1.5 "
Preservatives 0.3 "
Perfumed composition 0.2 "
Sodium hydroxide 0.3 "
Purified water q.s.to 100.0 "
Preparation of a lipogel containing complex the the of Krameria standardized extract.
100 g of gel contain Complex of standardized Krameria extract 0.1 g PEG-45 dodecylglycole copolymer 4.0 "
Hydroxystearate 4.0 "
Polyisoprene 37.5 "
Isopropyl myristate 3g.9 n Silicone oil 350 cps 3.5 "
Hydrogenated castor oil ~ 3.5 "
Colloidal silica 3.0 "
Polysorbate 80 3.0 "
Perfumed composition 0.5 g Preparation of a dusting powder containing the complex of the Krameria standardized extract.
100 g of powder contain Complex of Krameria standardized extract 0.1 g Colloidal silica 2.p "
Micronized hydrogenated castor oil 49.0 "
Maize starch 48.9 "
Antiinflammatory activity the Krameriaextract, of of the active components thereofand of the related com-plexes in the Croton oil in the mouse,at the maxi-test s mum edema (6 hours).
Substances Dose/mcg/ear Edema mg % reduction Controls --- .7.410.2 ---Eupomatenoid 6 56 1.50.2 78.5 **
28 4.50.1 40.2 Ratania-phenol* 56 1.90.2 73.7 **
28 4.70.2 34.8 Krameria extract 70 1.80.3 75.0 **
Phospholipid 157 6.50.3 10.2 78 6.20.2 14.0 Eupomatenoid/
complex 1M:11'~1 96 1.90.2 73.7 **
Krameria extr./
Complex lp:2p(w/w) 105 1.60.3 78.2 **
________________________________________________________ * 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
Distearoylphosphatidylcholine.
P<0.01 Student t.
The antiradical activity was evaluated using DPPH
as the competitor, accordingto proceduresdescribed in literature. Following Table obtained III reports the re-sults.
~~~1~3'~
_8-Table III
Antiradical activity of a Krameria standardized extract and of two components thereof.
Substances Conc.mcg/ml % destroyed DPNH
Eupomatenoid 6 6.6 -75.7 2.8 . -40.8 Ratania-phenol* 6.6 -80.5 2.8 -46.4 Krameria extract 10 -72.4 5 -41.6 Quercetin 6.2 -68.2 * 2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
In order to prepare the complexes with phospholi-pids, pure soy phosphatidylcholine or standardized mixtures of vegetable phospholipids with titres from 90°6 to 100°,~ or pure synthetic phospholipids having saturated or unsaturated acyl chains and choline or ethanolamine as the basic portion, were selected as the complexing agent s .
The formation of said complexes is ascertained by means of 1H-NMR, 13C-NMR, 31P-NMR spectroscopies and so lubility tests. As regards solubility, substances which are insoluble in aprotic solvents such as aromatic hydrocarbons, become easily soluble after complexation;
in the lIi-NMR spectrum the signals of complexed substances undergo a strong broadening, so as they can no more be evidenced in the spectra; in the 13C-NMR
spectrum the signals of the complexed substance, as well ".
_ g _ as those of the choline and glyceryl portions of the phospholipid, can no more be recorded; the phosphorus nucleus itself undergoes a band broadening, which indicates it is involved in the complex formation; in both the 1H and the 13C spectra, substantially only the lipid chain signals appear, even showing some immobilization. The above data prove the interaction between the phospholipid polar head and the active sites of the complex, whereas the lipid chains are not i0 involved, since they are free to rotate and can wind the complexed molecule giving it a marked lipophilia.
This winding clearly results in a particular steric ' configuration when the complex is dispersed in an aqueous medium, giving stability to the molecules them-selves.
The complexes of the present invention are insolu-ble in water and cannot form in this medium, therefore associations of the same products with phospholipids or liposomal preparations thereof do not give the same bio-logical results; the complexes of the invention, due to dipolarity reasons, in aqueous medium give rise to micellar microdispersions remarkably similar to the liposome structures. The novel structures according to the invention show, in comparison with the same structures in the free form, a different in vivo bioavailability which involves an increase in the specific activity as well as a longer lasting action by the topical route (skin and accessible mucosae).
For this class of substances, phospholipids are a selective carrier allowing the molecules to have both an improved crossing of the horny layer of the skin and a 202~.~~'~
better interaction with cell and bacterial walls. The molecules in the free form are restored and retained in the action site for a longer time. The presence of a surfactant, i.e. the phospholipid, in the molecule, al-lows to obtain a higher adhesion of the product itself to the surfaces it comes into contact with. This aspect is of paramount importance in cosmetic and pharmaceuti-cal formulations intended for the treatment of the oral cavity, in which contact times are of course very short;
the opportunity to increase the adhesion of the product to mucosae or to the tooth surface and to make the va-rious molecules interact with cell structures is of basic practical importance and it is an object of the present invention.
The dosages of the complexes of the invention can range widely, depending on the intended therapeutical purposes, and they can vary from 0.001 to 1°,6. The com-plexes of the present invention can be incorporated in the traditional pharmaceutical forms, such as ointments, fluid and thick 0/W or W/0 emulsions, solutions, chewa-ble tablets, dusting powders, or in form of plasters or medicated gauzes. Said preparations can be used in hu-mans or in animals for the treatment of superficial in-fected inflammatory processes, in torpid sores and in all the phlogistic conditions of the oral cavity; more particularly, as far as the oral cavity is concerned, they are an effective protection against the formation of dental plaque, when administered in form of medicated toothpaste, collutory or gel. In the cosmetic field, said complexes can be used for the treatment of acne and as deodorant, antidandruff and personal hygiene pro-ducts .
The following non limiting examples further illu-strate the invention.
Preparation of a standardized Krameria triandra extract.
kg of finely ground roots of Krameria triandra are extracted 4 times under mild reflux and nitrogen atmo-sphere with 4 volumes of methylene chloride; the combi-ned extracts are concentrated to small volume under nor-10 mal pressure. The concentrate is taken up into 5 1 of 90°,6 aqueous methanol and the solution is extracted 3 ti-mes with 1.5 1 of n-hexane; the hexane phase is discar-ded since it contains no active principles whereas the methanol phase is concentrated to 1.2 1; this concen-trace is extracted 3 times with 1.5 1 of methylene chlo-ride. The hydroalcoholic phase is discarded, whilst the chloromethylene extracts are pooled and treated with 25 g of decolorant charcoal in the presence of anhydrous sodium sulfate as the dehydrating agent; the decolorized chloromethylene solution is concentrated to small volume and the concentrate is poured into 1.5 1 of hexane, un-der. strong stirring. The precipitate is filtered and dried under vacuum overnight at 40°C, to obtain 300 g of a product containing about 50°,~ Eupomatenoids and 27%
2(2,4-dihydroxyphenyl)-5-propenylbenzofuran.
Preparation of Eupomatenoid 6 and 2-(2,4-dihydroxyphe-nyl)-5-propenylbenzofuran.
100 g of an extract prepared according to the pro cedures reported in Example 1 are chromatographed on a column containing 1.5 kg of silica gel, which has pre viously been equilibrated with a toluene/ethyl acetate 9:1 mixture, eluting the products with the same solvent mixture; the fractions showing a similar composition by thin layer chromatography are pooled and concentrated to dryness. The more abundant fraction, containing Eupoma-tenoid 6 (54 g) is crystallized from an hexane-isopropyl ether mixture, thus recovering the pure compound; analo-gously, the fraction containing the benzofuran deriva-tive is crystallized so as to isolate also this com-pound, the physico-chemical and speetroscopical charac-teristies of which are the same as those reported in li-terature.
Preparation of a purified Krameria extract by means of carbon dioxide under supercritical conditions.
1.5 kg of finely ground roots of Krameria are ex-tracted continuously in a suited reactor, fitted with heating and cooling mantle, with carbon dioxide under supercritical conditions, in two steps. A first step is carried out at a temperature of 35°C and under a pres-sure of 110 bars; in the evaporator temperature and pressure are 25°C and 50 bars, respectively. Two hours after, the extracted material is unloaded from the condenser and carbon dioxide containing 1.5% acetone is circulated in the extractor. The first extract, containing only lipophilic substances with no activity, is discarded, whereas the second extract is collected, which is obtained by increasing temperature to 45°C and pressure to 200 bars. The collected extract in the condenser is dissolved in isopropyl ether, the solution is dried over sodium sulfate and subsequently concentrated to small volume. The concentrate is poured into n-hexane . an abundant precipitate forms which, upon drying, weighs 46 g and has the same composition as that of the product obtained in Example 1, but it has a markedly lighter colour.
Preparation of the complex of the standardised extract of Krameria with soy phosphatidy~lcholine.
1.5 g of a purified Krameria triandra extract are dissolved together with 3 g of soy phosphatidylcholine in 30 ml of methylene chloride and heated to mild reflux for 2 hours; the chloromethylene solution is concentra ted to dryness under vacuum at 30°C until the solvent is completely evaporated off. The 1H-NMR spectrum of the obtained product shows protonic signals at 0.8 ppm of aliphatic methyls of the lipid chains and CH2 signals between 1.5 and 2.8 ppm, a very broad N-CH3 signal at about 3 ppm, signals of hydrogens on the double bond of aliphatic chains at 5.5 ppm and very broad, unresolved signals of aromatic protons of the Ratania-phenols at 6-8 ppm. In the 13C-NMR spectrum, the signals characteri-stics of Ratania-phenols between 102 and 135 ppm are absent or unresolved, and the signals of the carbons of phospholipid glycerin portion are also absent or extre-melt' broadened, as well as those of the choline portion.
Preparation of the complex of Eupomatenoid 6 with soy phosphatidylcholine.
2.8 g (O.OI mole) of Eupomatenoid 6 are dissolved together with 7.8 g (0.001 mole) of pure soy phospha tidylcholine in 30 ml of dioxane free from peroxides and the solution is freeze-dried; 10.5 g of a white product are obtained, having m.p. 98-101°C and spectroscopic characteristics in conformity with those of a complex.
1H-NMR (C6D6 solution): strong broadening of aromatic protons at 6-8 ppm; broadening of the N-CH3 signal at 3.3 ppm. The characteristic signals of lipid chains appear at 0.5-2 ppm. 13C-NMR (C6D6 solution) . absence of the signals of carbons of Eupomatenoid at 105-140 ppm and also of the lipid signals at 60-80 ppm.
Preparation of the complex of 2-(2,4-dihydroxyphenyl)-5-propenylbenzofuran with distearoylphosphatidylcholine.
2.78 g of 2-(2,4-dihydroxyphenyl)-S-propenylbenzo-furan are dissolved in 50 ml of dioxane together with 7.95 g of distearoylphosphatidylcholine and heated under strong stirring for 3 hours at SO°C, under argon atmo sphere. When dissolution is completed the whole is freeze-dried, to obtain a white-beige product having spectroscopic characteristics corresponding to those of a complex.
Preparation of a standardized extract of Eupomatia lau-rina.
10 kilograms of finely ground roots of Eupomatia laurina are extracted under weak reflux in a nitrogen atmosphere with 4 volumes of methylene chloride for four times and the pooled extracts are concentrated to a small volume at ordinary pressure. The concentrate is then dissolved in 2 1 of 90 per cent aqueous methanol and the resulting solution is extracted three times with 1.5 1 of petroleum ether.
The petroleum ether phase not containing the active principles is discarded and the methanolic phase is concentrated to 0.9 1. The latter concentrate is diluted with 300 ml of water and extracted three times with 0.8 1 of methylene chloride. The hydroalcoholic phase is discarded and the pooled methylene chloride extracts are treated with 25 g of decolorizing charcoal in the presence of anhydrous sodium sulphate as dehydrating agent. The decolorized methylene chloride solution is concentrated to a small volume and the concentrate is poured under vigorous shaking into 1 1 of hexane. After filtration of the precipitate and overnight drying under vacuum at 40°C, 190 g are obtained of a product which contains as a major component Eupomatenoide 6.
Preparation of the complex between the standardized extract of Eupomatia laurina and soy-bean phosphatidyl-choline.
g of purified extract of Eupomatia laurina are 20 dissolved together with 40 g of soy-bean phosphatidyl choline in 300 ml of methylene chloride and heated under weak reflux for 2 h. The methylene chloride solution is concentrated to dryness under vacuum at 30°C until the solvent has been completely removed. 'rhe 1H-NMR spectrum of the final product shows protonic singnals at 0.8 ppm originating from the aliphatic methyl group of the lipidic chains, CH2 signals between 1.5 and 2.8 ppm, a very broadened N-CH3 signal at around 3.4 ppm, signals from hydrogens on double bonds of aliphatic chains at S.S ppm and very broadened unresolved signals of the aromatic protons of phenols Eupomatenoide 6 like substances between 6.2 and 8 ppm. In the carbon spectra it is remarkable the absence or the lack of resolution of the typical signals of the Eupomatenoide like substances between 102 and 135 ppm and absence or the the extreme broadening of the signals the carbons of belonging to the glycerine and choline portions of the phospholipid. This complex is freely soluble in the chorinated solvents and in the vegetal, oils.
Preparation of a toothpaste containing complex of the the standardized Krameria extract.
100 g contain Complex of Rrameria standardized extract0.1 g Sodium carboxymethyl cellulose m.v. 1.0 "
Sorbitol 70% 20.0 ' Glycerin 18.0 "
Colloidal silica 15.0 "
Titanium dioxide 2.5 "
Maize starch 2.0 "
Sodium laurylsulfate 2.0 "
Sodium laurylsarcosinate 30% s. a. 1.0 "
Flavouring composition 1.0 ' Purified water q.s.to 100.0 "
Preparation of chewable tablets containingthe complex of Krameria standardized extract.
Each 1 g tablet contains Complex of Krameria standardized extract5.0 mg Methyl cellulose m.v. 2.0 "
Colloidal silica g.0 ~~
Magnesium stearate 10.0 "
-- 17 _ Mannitol 250.0 "
Glycamil (monoammonium glycyrrhizinate)5.0 "
Flavours 20.0 "
Saccharose (compressible) 700.0 mg Preparation of a medicated cream containing the complex Eupomatenoid/phosphatidylcholine.
100 g of an O/W emulsion contain Complex Eupomatenoid/phosphatidylcholine0.1 g PEG-8 C12-18 alkyl ester 10.0 "
Glyceryl stearate and PEG-8 stearate 2.5 "
Isopropyl myristate Preservative 0.1 "
Glycerin 5.0 ' Perfumed composition 0.5 "
Purified water q.s.to 100.0 g Preparation of an aqueous gel containingthe complex of the Krameria standardized extract 100 g of gel contain :
Complex of standardized Krameria extract0.1 g PEG-6 caprylic/capric glycerides 10.0 "
Ethoxylated oleyl alcohol 5.0 "
Carboxyvinyl polymer 1.5 "
Preservatives 0.3 "
Perfumed composition 0.2 "
Sodium hydroxide 0.3 "
Purified water q.s.to 100.0 "
Preparation of a lipogel containing complex the the of Krameria standardized extract.
100 g of gel contain Complex of standardized Krameria extract 0.1 g PEG-45 dodecylglycole copolymer 4.0 "
Hydroxystearate 4.0 "
Polyisoprene 37.5 "
Isopropyl myristate 3g.9 n Silicone oil 350 cps 3.5 "
Hydrogenated castor oil ~ 3.5 "
Colloidal silica 3.0 "
Polysorbate 80 3.0 "
Perfumed composition 0.5 g Preparation of a dusting powder containing the complex of the Krameria standardized extract.
100 g of powder contain Complex of Krameria standardized extract 0.1 g Colloidal silica 2.p "
Micronized hydrogenated castor oil 49.0 "
Maize starch 48.9 "
Claims (11)
1. Complexes of lipophilic extracts from plants of Krameria or Eupomatia genus, with natural or synthetic phospholipids.
2. Complexes of Ratania-phenols with natural or synthetic phospholipids.
3. Complexes of Eupomatenoid 6 with natural or synthetic phospholipids .
4. Complexes of 2-(2,4-dihydroxyphenyl)-5-propenylbenzo-furan with natural or synthetic phospholipids.
5. Complexes as claimed in the preceding claims, in which phospholipids are selected from soy phosphatidylcholine soy phosphatidylethanolamine, natural phospholipids having titres from 90 to 100% and pure synthetic phospholipids with saturated or unsaturated acyclic chains, having ethanolamine or choline as the basic portion.
6. A process for the preparation of lipophilic extracts from plants of Krameria or Eupomatia genus, which process consists in using carbon dioxide under supercritical conditions as the extraction solvent and in subsequently evaporating off said solvent.
7. A process as claimed in claim 6, in which process roots of Krameria triandra Ruiz et Pav. are subjected to extraction.
8. A process as claimed in claims 6 and 7, in which process extraction is carried out at temperatures around 40°C and under pressures of about 120 bars.
9. A process as claimed in claim 8, in which process, after the first extraction, the material is subjected to a second extraction with. carbon dioxide under supercritical conditions, at a temperature of about 45°C and under a pressure of about 200 bars.
10. A process as claimed in the preceding claims, in which process the obtained extract can subsequently be subjected to dehydration.
11. Pharmaceutical and cosmetic compositions having antiinflammatory, antibacterical, antimycotic and antiradical activities, containing as the active principles the complexes of claims 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2021637 CA2021637C (en) | 1990-07-20 | 1990-07-20 | Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2021637 CA2021637C (en) | 1990-07-20 | 1990-07-20 | Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2021637A1 CA2021637A1 (en) | 1992-01-21 |
| CA2021637C true CA2021637C (en) | 2001-01-30 |
Family
ID=4145533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2021637 Expired - Fee Related CA2021637C (en) | 1990-07-20 | 1990-07-20 | Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2021637C (en) |
-
1990
- 1990-07-20 CA CA 2021637 patent/CA2021637C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2021637A1 (en) | 1992-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5043323A (en) | Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them | |
| US5118671A (en) | Complexes of aescin, β-sitosterol or cholesterol, and phospholipids and pharmaceutical compositions containing them | |
| DE69919287T2 (en) | Ethyl acetate extract of indigo plant | |
| EP0464297B1 (en) | Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them | |
| EP1370564B1 (en) | Resveratrol-phospholipids complexes | |
| US8642646B2 (en) | Method and composition for treating acne using lignan compounds | |
| KR100973221B1 (en) | Novel use of Panduratin A or derivatives thereof | |
| EP3256142B1 (en) | Immunologically active plant mixture and use thereof for prophylaxis and in a method for treating efflorescence | |
| KR101231158B1 (en) | An antibacterial and antifungal composition containing the extracts and fractions of Hosta capitata as active ingredient | |
| DE3714937A1 (en) | NEW RETINIC ACID ESTERS FROM ANTIBIOTIKA, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THE SAME | |
| US6696404B1 (en) | Antibacterial composition having xanthorrizol | |
| JP2848688B2 (en) | Oral composition | |
| JPH06507390A (en) | Use of cucurbitin for the preparation of cosmetic or especially dermatological pharmaceutical antiallergic compositions and methods involving its application | |
| KR20060108864A (en) | Extract of chrysanthemum morifolium ramat, the preparation method thereof and the cosmetic composition comprising the same for whitening | |
| CA2021637C (en) | Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them | |
| JPS5916814A (en) | Composition for oral cavity | |
| JP3154712B2 (en) | Complex of neolignan derivative and phospholipid, use thereof, and pharmaceutical and cosmetic preparation containing the complex | |
| JPH11343247A (en) | Glucosyltransferase inhibitor | |
| JP3501855B2 (en) | Antibacterial / preservative and cosmetics containing jackfruit extract | |
| KR0162255B1 (en) | Complexes of neolignane derivatives with phospholipids, the use thereof and pharmaceutical and cosmetic formulations containing them | |
| KR100837682B1 (en) | An antibacterial and antifungal composition containing Dracocephalum foetidum extracts, Sophora alopecuroides extracts or fractions thereof | |
| KR20000073295A (en) | Method for separating material having antibiotic activity from Curcuma xanthorrhiza Roxb., the antibiotic material, and gargling agent, toothpaste composition and gum composition containing the antibiotic material | |
| KR100488493B1 (en) | Melanin biosynthesis inhibiting compounds purified from Angelica polymorpha, and whitening compositions the same | |
| DE19746284A1 (en) | Reducing odor of camomile extract or oil by cyclodextrin treatment, useful in pharmaceuticals and/or cosmetics having antiinflammatory activity | |
| KR20150004962A (en) | Cosmetic Composition for the Skin Whitening Comprising the Tabebuia avellanedae Extracts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |